C. Edward Chaplin
Known title: DirectorCIK: 0001237570
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
BHF Analyst Target Cut to $57, Rating Upgrade Amid Market Attention. KBW lowered its price target for BHF to $57, while a rating upgrade is expected after a pending acquisition. The stock has attracted attention following a 24% drop and its inclusion among life‑insurance names sensitive to rising Treasury yields. These developments add context to BHF’s valuation, which sits at a trailing P/E of 3.4 and an analyst average target of $65.
Transaction History
| MTG | ▲ Buy | Grant | 145 | — | 8/20/2026 | View on chart |
| BHF | ▲ Buy | Option Exercise | 4,556 | $0 | 6/2/2026 | View on chart |
| MTG | ▲ Buy | Grant | 150 | — | 5/21/2026 | View on chart |
| MTG | ▲ Buy | Grant | 146 | — | 3/6/2026 | View on chart |
| MTG | ▲ Buy | Grant | 5,077 | — | 2/4/2026 | View on chart |
| MTG | ▲ Buy | Grant | 113 | — | 11/20/2025 | View on chart |
| MTG | ▲ Buy | Grant | 114 | — | 8/21/2025 | View on chart |
| BHF | ▲ Buy | Option Exercise | 6,183 | $0 | 6/6/2025 | View on chart |
| MTG | ▲ Buy | Grant | 101 | — | 5/21/2025 | View on chart |
| MTG | ▲ Buy | Grant | 113 | — | 3/5/2025 | View on chart |
| MTG | ▲ Buy | Grant | 4,898 | $125K | 2/5/2025 | View on chart |
| MTG | ▲ Buy | Grant | 82 | — | 11/21/2024 | View on chart |
| MTG | ▲ Buy | Grant | 83 | — | 8/22/2024 | View on chart |
| BHF | ▲ Buy | Option Exercise | 5,947 | $0 | 6/6/2024 | View on chart |
| MTG | ▲ Buy | Grant | 86 | — | 5/21/2024 | View on chart |
| MTG | ▲ Buy | Grant | 89 | — | 3/5/2024 | View on chart |
| MTG | ▲ Buy | Grant | 6,310 | $125K | 2/2/2024 | View on chart |
| MTG | ▲ Buy | Grant | 59 | — | 11/28/2023 | View on chart |
| MTG | ▲ Buy | Grant | 61 | — | 8/24/2023 | View on chart |
| BHF | ▲ Buy | Option Exercise | 5,398 | $0 | 6/8/2023 | View on chart |
| MTG | ▲ Buy | Grant | 60 | — | 5/25/2023 | View on chart |
| MTG | ▲ Buy | Grant | 64 | — | 3/2/2023 | View on chart |
| MTG | ▲ Buy | Grant | 1 | — | 2/15/2023 | View on chart |
| MTG | ▲ Buy | Grant | 8,821 | $125K | 2/3/2023 | View on chart |
| MTG | ▲ Buy | Grant | 61 | — | 11/23/2022 | View on chart |
| MTG | ▲ Buy | Grant | 55 | — | 8/25/2022 | View on chart |
| BHF | ▲ Buy | Option Exercise | 5,806 | $0 | 6/8/2022 | View on chart |
| MTG | ▲ Buy | Grant | 49 | — | 5/26/2022 | View on chart |
| MTG | ▲ Buy | Grant | 45 | — | 3/2/2022 | View on chart |
| MTG | ▲ Buy | Grant | 8,085 | $125K | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Barclays Lifts MGIC Target to $29; AM Best Affirms Ratings
Barclays maintained an Equal-Weight rating on MGIC Investment while raising its price target to $29. In related news, AM Best affirmed the credit ratings of the company's operating subsidiaries. These updates provide a neutral backdrop as the stock trades near its 52-week low, with an average analyst target of $31.20.
Barclays Lifts MGIC Target to $29; AM Best Affirms Ratings. Barclays maintained an Equal-Weight rating on MGIC Investment while raising its price target to $29. In related news, AM Best affirmed the credit ratings of the company's operating subsidiaries. These updates provide a neutral backdrop as the stock trades near its 52-week low, with an average analyst target of $31.20.